HALOPER 5

מדינה: ישראל

שפה: אנגלית

מקור: Ministry of Health

מרכיב פעיל:

HALOPERIDOL

זמין מ:

CTS CHEMICAL INDUSTRIES LTD, ISRAEL

קוד ATC:

N05AD01

טופס פרצבטיות:

TABLETS

הרכב:

HALOPERIDOL 5.00 MG

מסלול נתינה (של תרופות):

PER OS

סוג מרשם:

Required

תוצרת:

CTS CHEMICAL INDUSTRIES LTD, ISRAEL

קבוצה תרפויטית:

HALOPERIDOL

איזור תרפויטי:

HALOPERIDOL

סממני תרפויטית:

Management of psychotic disorders. Control of tics and vocal utterances of Touratte's disorder in children and adults.

תאריך אישור:

2014-09-30

עלון מידע

PATIENT LEAFLET IN ACCORDANCE WITH THE
PHARMACISTS’ REGULATIONS )PREPARATIONS( –
1986
The medicine is dispensed with a doctor’s prescription only
HALOPER 0.5
mg tablets
HALOPER 5
mg tablets
HALOPER 10
mg tablets
Each tablet of Haloper 0.5 contains:
Haloperidol 0.5 mg
Each tablet of Haloper 5 contains:
Haloperidol 5 mg
Each tablet of Haloper 10 contains:
Haloperidol 10 mg
For inactive ingredients and allergens in the preparation –
see section 2 “Important information about some of the
ingredients of the medicine” and section 6 “Additional
information”.
READ THE ENTIRE LEAFLET CAREFULLY BEFORE USING THE
medicine. This leaflet contains concise information about
the medicine. If you have any other questions, refer to the
doctor or the pharmacist.
This medicine has been prescribed for treatment of your
illness. Do not pass it on to others. It may harm them even
if it seems to you that their medical condition is similar.
1. WHAT IS THE MEDICINE INTENDED FOR?
Haloper is intended for adult patients from 18 years of age
and above:
·
For treatment of schizophrenia and schizoaffective
disorder.
·
For acute treatment of acute confusion )delirium( after
failure of non-pharmacological treatments.
·
For treatment of moderate to severe manic episodes
related to bipolar disorder, when other treatments cannot
be used.
·
For treatment of acute psychomotor agitation related to
a psychotic disorder or to manic episodes due to bipolar
disorder.
·
For treatment of persistent aggression and psychotic
symptoms in patients with moderate to severe dementia
due to Alzheimer’s disease and vascular dementia after
failure of non-pharmacological treatments and when
there is a risk of self-harm or harm to others.
·
For treatment of tic disorders, including Tourette’s
syndrome, in patients with severe impairment after failure
of other educational, psychological and pharmacological
treatments.
·
For treatment of mild to moderate chorea in Huntington’s
disease, when other medical preparations are ineffective
or intolera